Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study

Journal of Dermatological Treatment

Volumn 17, Issue 6, 2006, Pages 343-352

  Gottlieb, Alice B ^a   Kircik, Leon ^b   Eisen, Drore ^c   Jackson, J Mark ^d   Boh, Erin E ^e   Strober, Bruce E ^f   Frankel, Ellen ^g   Xia, H Amy ^h   Stevens, Seth R ^h  

^a TUFTS MEDICAL CENTER   (United States)

^b Physicians Skin Care PLLC   (United States)

^c Dermatology Research Associates   (United States)

^d Dermatology Specialists   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Clinical Partners   (United States)

^h AMGEN INC   (United States)

Author keywords

Clinical trial; EDUCATE; Phase 4; Psoriasis; Psoriatic arthritis

Indexed keywords

ACETYLSALICYLIC ACID; CETIRIZINE; ETANERCEPT; FLUOXETINE; IBUPROFEN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PREDNISONE; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABSCESS; ADULT; AGED; APPENDECTOMY; APPENDICITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BODY SURFACE; BRONCHITIS; CELLULITIS; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIVERTICULITIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION IMPROVEMENT; GRANULOMATOSIS; HUMAN; INGUINAL ABSCESS; LIVER FUNCTION TEST; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; OPPORTUNISTIC INFECTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; SAMPLE SIZE; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; THERAPY EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 34250215268     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600967166     Document Type: Article

References (26)

1. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2004;17:350-63.
2. Ruderman EM. Evaluation and management of psoriatic arthritis: The role of biologic therapy. J Am Acad Dermatol. 2003;49:S125-32.
3. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh). 1989;146:69-71.
4. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc. 1978;53:511-8.
5. Scarpa R, Oriente P, Pucino A, Torella M, Vignone L, Riccio A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol. 1984;23:246-50.
6. Shbeeb M, Uramoto KM, Gibson LE, O'Fallon WM, Gabriel SE. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol. 2000;27:1247-50.
7. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med. 1987;62:127-41.
8. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford). 2003;42:1460-8.
9. Harrison BJ, Silman AJ, Barrett EM, Scott DG, Symmons DP. Presence of psoriasis does not influence the presentation or short-term outcome of patients with early inflammatory polyarthritis. J Rheumatol. 1997;24:1744-9.
10. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151-8.
11. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28:1842-6.
12. Husted JA, Gladman DD, Long JA, Farewell VT. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol. 1995;13:439-43.
13. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62:2447-57.
14. Mease PJ. Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61:298-304.
15. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003;49:S44-50.
16. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet. 2000;356:385-90.
17. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-72.
18. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol. 2002;138:657-63.
19. Enbrel® (etanercept) Full Prescribing Information, Thousand Oaks, CA: Amgen Inc. and Wyeth-Ayerst Pharmaceuticals, 2006.
20. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563-9.
21. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: Results from two randomized clinical trials. Health Qual Life Outcomes. 2003;1:53.
22. Cheah SY, Clark C, Goldberg L, Li Wan Po A, Phillips R. Outcome measures, pooled index and quality of life instruments in rheumatoid arthritis. J Clin Pharm Ther. 1996;21:297-316.
23. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-66.
24. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A comparison. J Drugs Dermatol. 2003;2:260-6.
25. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32; discussion 1632.
26. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.